AR056749A1 - Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso - Google Patents

Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso

Info

Publication number
AR056749A1
AR056749A1 ARP060104770A ARP060104770A AR056749A1 AR 056749 A1 AR056749 A1 AR 056749A1 AR P060104770 A ARP060104770 A AR P060104770A AR P060104770 A ARP060104770 A AR P060104770A AR 056749 A1 AR056749 A1 AR 056749A1
Authority
AR
Argentina
Prior art keywords
organoleptically
preparation
ibuprophen
dosage formulations
acceptable
Prior art date
Application number
ARP060104770A
Other languages
English (en)
Original Assignee
Teikoku Pharma Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa Inc filed Critical Teikoku Pharma Usa Inc
Publication of AR056749A1 publication Critical patent/AR056749A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Formulaciones de dosificacion oral solidas organolépticamente aceptables de ibuprofeno, y métodos para su preparacion y utilizacion. Una característica de las presentes formulaciones es que incluyen ibuprofeno y un componente de enmascaramiento. El componente de enmascaramiento incluye uno o más de un agente de enfriamiento, un ácido orgánico y una ciclodextrina. La presente encuentra utilidad en una variedad de aplicaciones.
ARP060104770A 2005-11-02 2006-10-31 Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso AR056749A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73312705P 2005-11-02 2005-11-02
US81041706P 2006-06-01 2006-06-01

Publications (1)

Publication Number Publication Date
AR056749A1 true AR056749A1 (es) 2007-10-24

Family

ID=38023574

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104770A AR056749A1 (es) 2005-11-02 2006-10-31 Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso

Country Status (12)

Country Link
US (1) US20070098789A1 (es)
EP (1) EP1942877A4 (es)
JP (2) JP2009514857A (es)
KR (1) KR20080034166A (es)
CN (1) CN103622926A (es)
AR (1) AR056749A1 (es)
AU (2) AU2006312119B2 (es)
BR (1) BRPI0618273A2 (es)
CA (1) CA2620219A1 (es)
RU (2) RU2008116871A (es)
TW (1) TW200733954A (es)
WO (1) WO2007055887A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055887A1 (en) * 2005-11-02 2007-05-18 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
AU2007308986A1 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
JP5821247B2 (ja) * 2010-04-07 2015-11-24 大正製薬株式会社 イブプロフェンの昇華抑制方法
CA2833105C (en) * 2011-04-11 2019-04-23 Ayanda Group As Oral pharmaceutical dispersion compositions
CN102258490B (zh) * 2011-07-01 2012-10-03 中美天津史克制药有限公司 布洛芬咀嚼片
US9914968B2 (en) 2012-09-26 2018-03-13 Cepheid Honeycomb tube
FR2997856B1 (fr) * 2012-11-14 2015-04-24 Pf Medicament Pastille medicamenteuse a base d'ibuprofene sodique dihydrate
CN103690474B (zh) * 2013-12-04 2015-09-30 郑州大明药物科技有限公司 布洛芬乳膏的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
CH677606A5 (es) * 1988-07-12 1991-06-14 Aesculapius Pharma Sa
US4916161A (en) * 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US5055461A (en) * 1989-02-15 1991-10-08 Richardson-Vicks Inc. Anesthetic oral compositions and methods of use
JPH0426618A (ja) * 1990-05-21 1992-01-29 Japan Tobacco Inc トローチ剤
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries Ltd Schnellösliche Tablette und ihre Herstellung
GB9207990D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Pharmaceutical composition
EP0695175A1 (en) * 1993-04-30 1996-02-07 The Procter & Gamble Company Coated pharmaceutical compositions
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5616344A (en) * 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5560913A (en) * 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
TW442287B (en) * 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
ATE210428T1 (de) * 1995-10-17 2001-12-15 Reckitt Benckiser Healthcare Geschmacksmaskierte wässrige lösungen enthaltend ibuprofen und menthol
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5912007A (en) * 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
ZA976189B (en) * 1996-07-12 1999-01-11 Novartis Consumer Health Sa Oral pharmaceutical combinations
GB9710521D0 (en) * 1997-05-22 1997-07-16 Boots Co Plc Process
ES2224634T3 (es) * 1998-04-29 2005-03-01 Sumitomo Pharmaceuticals Company, Limited Formulacion oral que comprende biguanida y un acido organico.
US20020110581A1 (en) * 1999-04-06 2002-08-15 Ream Ronald L. Over-coated product including consumable center and medicament
US20050042271A1 (en) * 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
WO2003009834A1 (en) * 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
JP3553562B2 (ja) * 2000-08-25 2004-08-11 興和株式会社 イブプロフェンカプセル充填液及びカプセル製剤
IT1319229B1 (it) * 2000-10-20 2003-09-26 Savio Macchine Tessili Spa Dispositivo portarocche perfezionato per avvolgimento di filato conpressione regolata, particolarmente per ritorcitoi a doppia torsione.
EP1391201A4 (en) * 2001-05-25 2004-06-30 Ssp Co Ltd MEDICAL COMPOSITIONS
US8859028B2 (en) * 2002-06-14 2014-10-14 Cereal Ingredients, Inc. Coated food particle and method for making a swirl
GB0217382D0 (en) * 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
US20040071852A1 (en) * 2002-10-09 2004-04-15 Yael Vodovotz Compositions and processes for making high soy protein-containing bakery products
AU2003271552B2 (en) * 2002-10-11 2009-04-23 Novozymes A/S Method of preparing a heat-treated product
JP4815867B2 (ja) * 2004-05-11 2011-11-16 大正製薬株式会社 安定化された固形製剤
US20060263475A1 (en) * 2004-08-25 2006-11-23 Cadbury Adams Usa, Llc. Center-filled chewing gum composition
CN101102748A (zh) * 2004-12-23 2008-01-09 麦克内尔-Ppc股份有限公司 具有感觉提示剂的在口中分裂的药物组合物
WO2007055887A1 (en) * 2005-11-02 2007-05-18 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Also Published As

Publication number Publication date
RU2008116871A (ru) 2009-12-10
TW200733954A (en) 2007-09-16
BRPI0618273A2 (pt) 2011-08-23
EP1942877A4 (en) 2011-09-14
EP1942877A1 (en) 2008-07-16
AU2006312119B2 (en) 2010-04-29
US20070098789A1 (en) 2007-05-03
AU2010202050A1 (en) 2010-06-10
JP2012255018A (ja) 2012-12-27
JP2009514857A (ja) 2009-04-09
CA2620219A1 (en) 2007-05-18
KR20080034166A (ko) 2008-04-18
WO2007055887A1 (en) 2007-05-18
CN103622926A (zh) 2014-03-12
RU2012138581A (ru) 2014-03-20
AU2006312119A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
AR056749A1 (es) Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
CL2008000893A1 (es) Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal.
BRPI0518187A (pt) formulações de olanzapina em nanopartìcula injetáveis
ES2422556T3 (es) Tratamiento de hepatitis vírica
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
GT200600097A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
GT200600307A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
GT200900082A (es) Composiciones de fenilalquilamino-carbamato
CL2011001131A1 (es) Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp)
AR109263A2 (es) Composición que comprende moxidectina
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CO6321237A2 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
CL2007003877A1 (es) Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal